Online Only Articles

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

University Hospital, Nantes, France
Cherkassy Regional Oncology Dispensary, Cherkassy, Ukraine
Medical University of Silesia, Katowice, Poland
Kiev BMT Center, Kiev, Ukraine
Hopital Huriez, CHRU, Lille, France
Khmelnitskiy Regional Hospital, Khmelnitskiy, Ukraine
SI Institute of Blood Pathology and Transfusion Medicine UAMS, Lviv, Ukraine
Medical University of Lodz, Lodz, Poland
Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA
Janssen Research & Development, LLC, Raritan, NJ, USA
Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium
Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium
Immuno-hématologie Department, Hôpital Saint-Louis, Paris, France
Vol. 100 No. 5 (2015): May, 2015 https://doi.org/10.3324/haematol.2014.118182